Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABMIL:1GETI 52 EV-to-EBIT is 16.48 as of Aug. 12, 2026, which is 7% below its 10-year median of 17.65. GuruFocus rates MIL:1GETI with a GF Score™ of 52/100 and a GF Value™ of €17.65 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Getinge AB ranks better than 58.47% on this metric.
The historical rank and industry rank for Getinge AB's EV-to-EBIT or its related term are showing as below:
MIL:1GETI'
s EV-to-EBIT Range Over the Past 10 Years
Min: -193.77 Med: 17.65 Max: 258.98
Current: 16.56
During the past 13 years, the highest EV-to-EBIT of Getinge AB was 258.98. The lowest was -193.77. And the median was 17.65.
MIL:1GETI's EV-to-EBIT is ranked better than 58.47% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.215
vs MIL:1GETI: 16.56
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Getinge AB's Enterprise Value for the quarter that ended in Jun. 2026 was €5,486 Mil.
Getinge AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €411 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB EV-to-EBIT Related Terms
Getinge AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Getinge AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Getinge AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Getinge AB's EV-to-EBIT falls into.
Getinge AB's current Enterprise Value is €6,769 Mil.
Getinge AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €411 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (MIL:1GETI) has a EV-to-EBIT of 16.48 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Getinge AB and its competitors. This is near median its historical median of 17.65. According to the industry distribution chart, Getinge AB ranks #196 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 41.5%.
Is Getinge AB's EV-to-EBIT too high?
Getinge AB's current EV-to-EBIT of 16.48 is near median its 10-year median of 17.65. The Medical Devices & Instruments industry median EV-to-EBIT is 19.22. Getinge AB's value of 16.48 is 14.2% below this industry median. Based on the distribution chart, Getinge AB ranks #196 out of 472 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getinge AB has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #196 out of 472 companies for EV-to-EBIT. This puts Getinge AB in the upper half of its industry. The industry median EV-to-EBIT is 19.22. Getinge AB's value of 16.48 is 14.2% below this benchmark. While the company's 10-year median is 17.65 vs. the industry median of 19.22, Getinge AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.22, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current EV-to-EBIT of 16.48 is 14.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current EV-to-EBIT is 16.48, which is near median its own 10-year median of 17.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (MIL:1GETI) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.65, compared to a current price of €20.90 — trading 18.4% above its estimated fair value. The current EV-to-EBIT is 16.48, which is near median its 10-year median of 17.65 and 14.2% below the Medical Devices & Instruments industry median of 19.22. Getinge AB's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Getinge AB (MIL:1GETI), the current EV-to-EBIT is 16.48 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (MIL:1GETI) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of €20.90 is trading 18.4% above its estimated GF Value™ of €17.65.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for MIL:1GETI:
EV-to-EBIT: 16.48 (near median its 10-year median of 17.65)
GF Value™: €17.65 vs. price of €20.90 (18.4% above fair value)
Industry Position: 14.2% below the Medical Devices & Instruments median (#196 of 472)
No single metric tells the full story. See the MIL:1GETI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
52GF Score
Get the complete analysis for MIL:1GETI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1GETI has been successfully added to your 
